Categories: All postsAnalysts

Is Lightspeed (TSX:LSPD) undervalued?

ATB Capital Markets analyst Martin Toner says Lightspeed Commerce’s (Lightspeed Commerce Stock Quote, Chart, News, Analysts, Financials TSX:LSPD) Q1 results showed stronger-than-expected revenue, but gross margin pressure and a slight Adjusted EBITDA miss kept the stock in neutral territory.

In a July 31 update, Toner maintained his “Sector Perform” rating and $18.00 target on Lightspeed. His target implies a 33% return.

Lightspeed reported Q1 fiscal 2027 revenue of $322.7-million, up 5.8% year-over-year on a reported basis and 17% organically, ahead of consensus at $311.0-million. Gross profit was $138.6-million, representing a 42.9% gross margin.

Adjusted EBITDA was $17.5-million, slightly below consensus at $18.0-million, while net loss narrowed to $2.4-million.

Toner said revenue was supported by software growth and payments adoption, while gross margin was pressured by hardware supply chain costs and payment mix.

Gross payment volume reached $11.3-billion, with payment penetration of 44%. Monthly average revenue per user increased 13% organically to about $676.

Customer locations in Lightspeed’s core growth engines rose 10% year-over-year, within management’s long-term target range of 10% to 15%. Net location additions of 1,300 reflected seasonal Q1 softness and the removal of about 500 low-ARPU locations tied to the termination of a legacy white-label agreement.

During the quarter, Lightspeed repurchased and cancelled about 6.97-million shares for $65.1-million under its normal course issuer bid.

Toner said management’s 10% reduction in product and technology staff after quarter-end should lower R&D expenses beginning in Q2. He also expects hardware margins to improve in the second half of fiscal 2027 as cost controls take effect.

For Q2, Toner forecasts revenue of $319.5-million and Adjusted EBITDA of $22.2-million, in line with management’s Adjusted EBITDA guidance of $20-million to $25-million.

He now expects Lightspeed to generate Adjusted EBITDA of $86.1-million on revenue of $1.26-billion in fiscal 2027, followed by Adjusted EBITDA of $147.6-million on revenue of $1.45-billion in fiscal 2028.

Toner said his $18.00 target is based on a discounted cash flow valuation using a 16.0% discount rate and 2.5% terminal growth rate.

 

-30-

Tagged with: lspd
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Gain Therapeutics: this analyst just chopped his target

Roth Capital Partners analyst Boobalan Pachaiyappan lowered his target on Gain Therapeutics (Gain Therapeutics Stock Quote, Chart, News, Analysts, Financials… [Read More]

9 hours ago

WELLSTAR Technologies is off to a great start, this analyst says

WELLSTAR Technologies’ (WELLSTAR Technologies Corp. Stock Quote, Chart, News, Analysts, Financials TSXV:WSTR) first quarterly results as a public company exceeded… [Read More]

9 hours ago

This Canadian stock benefits from increased defense spending, analyst says

Volatus Aerospace’s (Volatus Aerospace Stock Quote, Chart, News, Analysts, Financials TSX:FLT) first Canadian Armed Forces contract and growing defence order… [Read More]

15 hours ago

Buy WELL Health Technologies for a double, this analyst says

WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) Canadian clinic operations delivered strong third-quarter growth,… [Read More]

19 hours ago

Is Quarterhill (TSX:QTRH) an undervalued stock?

Quarterhill (Quarterhill  Stock Quote, Chart, News, Analysts, Financials TSX:QTRH) remains on track to complete its acquisition of Conduent’s tolling business… [Read More]

20 hours ago

This Canadian biotech stock is undervalued, analyst says

Medicenna Therapeutics’ (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) experimental cancer treatment MDNA11 produced encouraging responses in patients… [Read More]

20 hours ago